Some key points in my mind are: 1. contracts by late April/early May 2. The ALRT HeC system can save Medicare and others billions annually---more than $9 billion due to poor adherence; and $200 million plus due to waste and abuse. 2. cash flow potential at $4.50 a share. My caluclations show this should result in a share price of $90.00 or higher. And this was from only insulin dependent diabetics 4. They will expand to other disease management areas. Mission is to become the leading disease management platform globally.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.